score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable			Clinical evidence	Copy Number	MYC	Amplification				0.0	0.0																Putatively Actionable	0.0	Poor prognosis (< 15%) was observed for patients with amplified MYC with Medulloblastoma.	Ryan SL, Schwalbe EC, Cole M, et al. MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. Acta Neuropathol. 2012;123(4):501-13.	https://doi.org/10.1007/s00401-011-0923-y	0				MYC Amplification		Osteosarcoma-NAN358	NAN358_T	
Investigate Actionability	Inferential			Mutational Signature	COSMIC Signature 4	version 2	0.376						Investigate Actionability	Pembrolizumab	PD-1/PD-L1 inhibition	Immunotherapy	"In a cohort of 34 non-small cell lung cancer patients with pembrolizumab, the presence of a smoking signature (""transversion-high"" tumors) was associated with a higher overall response rate (56% in transversion-high tumors, vs. 17% in ""transversion-low"" [never-smoker] tumors), a higher rate of DCB (77% vs. 22%), and a longer PFS."	Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124-8.	https://doi.org/10.1126/science.aaa1348													0				COSMIC Signature (version 2) 4 (38%)		Osteosarcoma-NAN358		
Investigate Actionability		Guideline	Guideline	Somatic Variant	TP53	Missense	p.R337L	0.1111	54.0	0.0	0.0									Investigate Actionability	Lenalidomide	Immunomodulation	Targeted therapy	More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	Investigate Actionability	0.0	Missense mutation in any codon except P47S or P72R is associated with a poor prognosis and possible resistance to lenalidomide. More frequent with complex karyotypes and del(5q).	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0				TP53 p.R337L (Missense)		Osteosarcoma-NAN358	Osteosarcoma-NAN358-Tumor-SM-2RCBF	Osteosarcoma-NAN358-Normal-SM-2RCCU
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		Osteosarcoma-NAN358		
Biologically Relevant				Mutational Signature	COSMIC Signature 30	version 2	0.292																									0				COSMIC Signature (version 2) 30 (29%)		Osteosarcoma-NAN358		
